niacinamide has been researched along with Endocarditis, Loeffler in 6 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib was originally developed as a BRAF inhibitor, but our work demonstrates that sorafenib can also be used to treat FIP1L1-PDGFRA positive leukemia, demonstrating that new therapies to treat rare leukemias may be simply found by testing drugs that are already in use for the treatment of other diseases." | 1.36 | Identification and characterization of novel oncogenes in chronic eosinophilic leukemia and T-cell acute lymphoblastic leukemia. ( Cools, J, 2010) |
| "Chronic eosinophilic leukemia (CEL) is a rare myeloproliferative neoplasm characterized by the FIP1L1-PDGFRA fusion gene, variant PDGFRA fusions or other genetic lesions." | 1.35 | FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. ( Beullens, E; Cools, J; Lierman, E; Marynen, P; Michaux, L; Pierre, P; Vandenberghe, P, 2009) |
| "Sorafenib was recently approved for the treatment of renal cell carcinoma." | 1.33 | Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. ( Boogaerts, M; Cools, J; Folens, C; Lierman, E; Marynen, P; Mentens, N; Scheers, W; Stover, EH; Van Miegroet, H; Vandenberghe, P, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Salemi, S | 1 |
| Yousefi, S | 1 |
| Simon, D | 1 |
| Schmid, I | 1 |
| Moretti, L | 1 |
| Scapozza, L | 1 |
| Simon, HU | 1 |
| Lierman, E | 2 |
| Michaux, L | 1 |
| Beullens, E | 1 |
| Pierre, P | 1 |
| Marynen, P | 2 |
| Cools, J | 3 |
| Vandenberghe, P | 2 |
| Antoniu, SA | 1 |
| Metzgeroth, G | 1 |
| Erben, P | 1 |
| Martin, H | 1 |
| Mousset, S | 1 |
| Teichmann, M | 1 |
| Walz, C | 1 |
| Klippstein, T | 1 |
| Hochhaus, A | 1 |
| Cross, NC | 1 |
| Hofmann, WK | 1 |
| Reiter, A | 1 |
| Folens, C | 1 |
| Stover, EH | 1 |
| Mentens, N | 1 |
| Van Miegroet, H | 1 |
| Scheers, W | 1 |
| Boogaerts, M | 1 |
1 review available for niacinamide and Endocarditis, Loeffler
| Article | Year |
|---|---|
Novel therapies for hypereosinophilic syndromes.
Topics: Adrenal Cortex Hormones; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2010 |
5 other studies available for niacinamide and Endocarditis, Loeffler
| Article | Year |
|---|---|
A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
Topics: Amino Acid Sequence; Benzamides; Benzenesulfonates; Chronic Disease; Drug Resistance; Humans; Hypere | 2009 |
FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.
Topics: Aged; Animals; Benzenesulfonates; Blast Crisis; Blotting, Western; Cells, Cultured; Chronic Disease; | 2009 |
Identification and characterization of novel oncogenes in chronic eosinophilic leukemia and T-cell acute lymphoblastic leukemia.
Topics: Benzenesulfonates; Humans; Hypereosinophilic Syndrome; mRNA Cleavage and Polyadenylation Factors; Ni | 2010 |
Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Chronic Disease; Drug | 2012 |
Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.
Topics: Benzamides; Benzenesulfonates; Carcinoma; Cell Proliferation; Drug Evaluation, Preclinical; Drug Res | 2006 |